Articles, insights, and posts about Child Development, early detection, and new methods in diagnosis and treatment.
The performance of FDNA’s facial analysis technology, Face2Gene, was recently put up to the challenge of recognizing facial features of children ages 2-6 with CHARGE syndrome compared to a control group of children with other syndromes. The results demonstrate that this technology successfully recognizes children with CHARGE syndrome with a high degree of accuracy (measured […]
Annual Clinical Genetics Meeting (ESHG 2017) Bella Center Copenhagen, Copenhagen, Denmark May 27-30, 2017 Copenhagen, Denmark – The time is yet again upon us here at FDNA to pack our bags and make the exciting journey across the pond to attend ESHG. While in Copenhagen, we are looking forward to connecting with colleagues, old and new, while […]
In March, FDNA reached out to clinicians and patients globally as part of the Year of Discovery to collect and analyze patient data from a category of syndromes known as RASopathies, in partnership with Blueprint Genetics and the Noonan Syndrome Foundation. A research team at FDNA, dedicated to making new discoveries with this data, has released […]
FDNA’s Year of Discovery Initiative is taking on a different genetic syndrome group each month as part of its mission to accelerate advancements and discoveries for all rare diseases. FDNA launched the Year of Discovery on February 28, 2017 to use cutting-edge technologies to advance rare disease research. In April, FDNA is partnering with Invitae […]
This month in the Year of Discovery, FDNA spotlights syndromes categorized as RASopathies. Every case uploaded in March will be matched with a $1 donation sponsored by Blueprint Genetics and benefiting the Noonan Syndrome Foundation.* Every time a patient’s case is analyzed by Face2Gene, the de-identified information will train the system to recognize new associations […]
Dekel Gelbman, CEO of FDNA, was featured in Health Data Management discussing the value for hospitals of using clinical data warehouses for the storage and analysis of genomic and phenotypic information. Below is an excerpt: There are more than 7,000 rare diseases for physicians to consider when diagnosing a patient. For even the most experienced […]
FDNA’s Year of Discovery Initiative will spotlight a different genetic syndrome group each month as part of their mission to accelerate advancements and discoveries for all rare diseases. Boston, MA. March 9, 2017— FDNA launched the Year of Discovery on February 28th, 2017 to unite clinicians, labs and patients for rare disease advancements. March, the […]
Annual Clinical Genetics Meeting (ACMG 2017) Phoenix Convention Center, Phoenix, Arizona March 21-25, 2017 Phoenix, Arizona – With ACMG just over a week away, the FDNA team is growing increasingly excited to trade in our winter coats and boots for sunshine and cacti. But the escape from the everlasting Boston winter aside, is the anticipation to […]
Dekel Gelbman, CEO of FDNA, was featured in the Medical Device and Diagnostics Industry, discussing the value of facial analysis technology and phenotyping in discovering rare disease diagnoses. Below is an excerpt: Diagnosing rare and ultra-rare genetic diseases can be extremely difficult for geneticists. The diagnostic odyssey, from the primary point of care, through the […]